Hims & Hers CTO Mohamed Elshenawy Receives 1.2M RSU Award

What Happened Mohamed Elshenawy, Chief Technology Officer of Hims & Hers Health, Inc. (HIMS), was granted 1,200,000 restricted stock units (RSUs) on 2026-08-12. The Form 4 reports the award as a derivative acquisition at $0.00 per unit (reported value $0 at grant). Each RSU represents a contingent right to receive one share of Class A common stock upon vesting.

Key Details

• Transaction date: 2026-08-12; Form 4 filed: 2026-08-14. Filing appears timely under the standard two-business-day Form 4 deadline.
• Transaction type/code: Award/Grant (A).
• Amount: 1,200,000 RSUs; reported price: $0.00; reported value at grant: $0.
• Shares owned after transaction: Not specified in the provided filing.
• Footnotes: F1 — RSUs convert 1:1 into Class A common stock upon vesting. F2 — Vesting is service-based over a 3-year period, vesting in substantially equal quarterly installments on the company’s quarterly vesting dates; the first vesting occurs on the first company quarterly vesting date after the grant.
• Derivative note: RSUs are a contingent/derivative award, not an open-market purchase or sale.

Context RSU grants are a form of executive compensation intended to align long-term incentives; they do not represent immediately tradable shares and involve no upfront cash outlay by the executive. The economic value to the insider depends on HIMS’s future share price at each vesting date and the completion of the service-based vesting schedule. This grant should be viewed as compensation rather than a direct bullish or bearish trading signal.